CHGCY (Chugai Pharmaceutical Co) Tariff Resilience Score : 7/10 (As of Jul. 09, 2025)

View and export this data going back to 2008. Start your Free Trial

What is Chugai Pharmaceutical Co Tariff Resilience Score?

Chugai Pharmaceutical Co has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Chugai Pharmaceutical Co has Chugai Pharmaceutical has moderate tariff exposure due to its global operations. However, its strong R&D and potential for tariff exemptions on pharmaceuticals provide resilience against tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Chugai Pharmaceutical Co might have Highly Resilient.

Competitive Comparison of Chugai Pharmaceutical Co's Tariff Resilience Score

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chugai Pharmaceutical Co's Tariff Resilience Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Tariff Resilience Score falls into.

Save Embed

;

Save Embed

;

Chugai Pharmaceutical Co (OTCPK:CHGCY) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score	Resilience Level
7 - 10	Highly Resilient
4 - 6	Average Resilient
0 - 3	Highly Vulnerable

Chugai Pharmaceutical Co Tariff Resilience Score Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Tariff Resilience Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Chugai Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCY) » Definitions » Tariff Resilience Score

Comparable Companies

Traded in Other Exchanges

CHGCF:USA 4519N:Mexico 4519:Japan CUP:Germany

Address

1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324

Website

http://www.chugai-pharm.co.jp

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and Actemra for treating rheumatoid arthritis and covid patients.